Rising prevalence of ovarian cancer and growing focus on early detection and treatment are expected to fuel market growth.
Rising prevalence of ovarian cancer and growing focus on early detection and treatment are expected to fuel market growth.
The global ovarian cancer diagnostics market size is expected to reach USD 2.3 billion in 2028, registering a CAGR of 6.7% over the forecast period, according to the latest report by Reports and Data. Major factors driving market revenue growth are rising prevalence of ovarian cancer and increasing awareness about the importance of early detection of ovarian cancer.
Ovarian cancer is the world’s seventh most common cause of death and morbidity in women. It is a complex neoplasm that often affects women over 65 years old. The age group of 50–79 years was identified as the average for diagnosis in various studies. Women have a one-in-75 chance of contracting ovarian cancer during their lifetime, and one-in-one-hundred chance of dying from it. The disease’s prevalence tends to vary by age and race, with the latter being higher in less developed countries. From 1982 to 2008, the incidence rate of ovarian cancer in Europe increased dramatically, increasing from 4.9 to 6.1 per 100,000 females. Ovarian cancer accounted for 81.8 percent of all cancer cases in the U.S. in 2012.
Age is a considerable risk factor in for ovarian cancer. It is most common among women aged between 50 and 79. As the geriatric population of the world rises, ovarian cancer is becoming more common, and there is a greater focus on early detection and treatment, which is expected to fuel ovarian cancer diagnostic market growth. Furthermore, increasing government investments in raising awareness about early cancer detection and rising health-care spending will also drive market growth.
Research shows that obesity plays a considerable role in increasing the chances of ovarian cancer. Other lifestyle choices, such as smoking and drinking as well as not having any children, can also increase the chances of the disease. Since ovarian cancer is often not detected in time, women who are at risk of developing the tumour need to undergo regular testing to catch the diseases early, which is boosting the growth for the market.
Key factors limiting growth of the market are lack of information about exact causative factors and late diagnosis of the disease. A deeper understanding of the underlying molecular processes is urgently needed in order to identify key genes or biochemical pathways that could be targeted for diagnosis and treatment.
Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/4093
Some Key Highlights in the Report:
- Epithelial tumours segment is expected to account for largest market share over the coming years.
- Imaging techniques segment is expected to register a robust CAGR among the diagnosis type segments during the forecast period.
- Hospital laboratories segment accounted for largest revenue share among end user segments in the global market in 2020.
- Ongoing research and development in the ovarian cancer diagnostics market in North America will contribute to the relatively higher market share held by the region.
- Due to factors, such as overall economic growth, improved healthcare infrastructure, increased disposable income, and increased awareness, Asia Pacific ovarian cancer diagnostics market is expected to expand at the fastest pace during the forecast period.
- Some of the prominent players in the ovarian cancer diagnostics market include F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson Services, Inc.; AstraZeneca plc; Siemens Healthcare GmbH; Quest Diagnostics Incorporated.; Thermo Fisher Scientific; Bio-Rad Technologies Inc.; and Abbott.
Buy now your Exclusive copy of Report @ https://www.reportsanddata.com/checkout-form/4093
Segments covered in the report:
For the purpose of this report, Reports and Data has segmented the global ovarian cancer diagnostics market on the basis of cancer type, diagnosis type, end user and region:
Cancer Type Outlook (Revenue, USD Billion; 2018 – 2028)
- Epithelial Tumour
- Germ Cell Tumour
- Stromal Cell Tumour
- Others
Diagnosis Type Outlook (Revenue, USD Billion; 2018 – 2028)
- Imaging
- Ultrasound
- CT Scan
- MRI Scan
- PET Scan
- Others
- Blood Test
- CA125
- HER2
- BRCA
- CEA
- ER & PR
- KRAS Mutation
- Others
- Biopsy
- Others
Request for Custom Research @ https://www.reportsanddata.com/request-customization-form/4093
End User Outlook (Revenue, USD Billion; 2018 – 2028)
- Hospital Laboratories
- Cancer Diagnostic Centers
- Research Institutes
- Others
Regional Outlook (Revenue, USD Billion; 2018 – 2028)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
Explore Reports and Data’s Prime Analysis of the global Pharmaceutical & Healthcare Industry:
Lung Cancer Diagnostics Market Size, Share & Analysis, By Lung Cancer Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test Type (Imaging, Biopsy, Sputum Cytology, Molecular Testing, Others), By End-User (Hospitals & Clinics, Diagnostic Centers, Research Institutes, Others), And Region, Segment Forecasts To 2027
Prostate Cancer Diagnostics Market Size, Share & Analysis, By Prostate Cancer Type (Acinar Adenocarcinoma, Ductal Adenocarcinoma, Transitional Cell (or Urothelial) Cancer, Squamous Cell Cancer, Small Cell Prostate Cancer, Others), By Test Type (Preliminary Tests, Confirmatory Tests), By End-User (Hospitals & Clinics, Diagnostic Centers, Research Institutes, Others), And Region, Segment Forecasts To 2027
Liver Cancer Diagnostics Market Size, Share & Analysis, By Screening Type (Laboratory Tests, Imaging, Endoscopy, Biopsy, Others), By End-User (Hospitals, Diagnostic Centers, Diagnostic Imaging Centers, Cancer Research Institutes, Others), And By Region, Forecast To 2028
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Read Full Press Release: https://www.reportsanddata.com/press-release/global-ovarian-cancer-diagnostics-market